Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Stamm

Showing results (151-160 of 155) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 155 results.
Gastroenterology|April 10, 2017
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized TrialsIra M Jacobson, Eric Lawitz, Edward J Gane, et al.
The New England Journal of Medicine|June 1, 2017
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV InfectionMarc Bourlière, Stuart C Gordon, Steven L Flamm, et al.
Journal of Hepatology|June 13, 2022
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infectionMark S Sulkowski, Kosh Agarwal, Xiaoli Ma, et al.
Journal of Hepatology|April 23, 2022
Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infectionMan-Fung Yuen, Kosh Agarwal, Xiaoli Ma, et al.
The Lancet. Gastroenterology & Hepatology|December 18, 2018
Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trialLai Wei, Seng Gee Lim, Qing Xie, et al.
Pageof 16

Showing results (151-160 of 155) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 155 results.
Gastroenterology|April 10, 2017
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized TrialsIra M Jacobson, Eric Lawitz, Edward J Gane, et al.
The New England Journal of Medicine|June 1, 2017
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV InfectionMarc Bourlière, Stuart C Gordon, Steven L Flamm, et al.
Journal of Hepatology|June 13, 2022
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infectionMark S Sulkowski, Kosh Agarwal, Xiaoli Ma, et al.
Journal of Hepatology|April 23, 2022
Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infectionMan-Fung Yuen, Kosh Agarwal, Xiaoli Ma, et al.
The Lancet. Gastroenterology & Hepatology|December 18, 2018
Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trialLai Wei, Seng Gee Lim, Qing Xie, et al.
Pageof 16